Earnings Analysis July 28, 2026

GSK ($GSK) Q2 2026 Earnings Analysis — Revenue Beats Consensus, Guidance Tops of Ranges

Earnings Scorecard

Revenue: £8.4 billion (+5% year-over-year at constant exchange rates / slightly above market consensus, with variation across providers) ✅ Beat

EPS: Core 50.5 pence (+9% year-over-year) — Core EPS is reported in pence, making direct comparison with US ADR dollar consensus difficult

Guidance: Maintained (top-of-range signaled) — Full-year revenue growth 3–5% guided to upper half, core operating profit growth 7–9% also upper half, core EPS growth 7–9% lower half

Stock Reaction: Released before US market open — need to confirm post-open reaction

The Positives

Specialty Medicines +14%: Quarterly revenue of £3.8 billion, serving as the core growth engine

Vaccines rebound +8%: £2.3 billion, turning the previously soft segment back to positive growth

Margin improvement: Core operating profit +7%, core EPS +9% — growing faster than revenue

The character of this quarter can be summarized in one phrase: "confirmation of a structural transformation." GSK is a UK-headquartered global pharmaceutical company. Historically, it leaned heavily on General Medicines (cold remedies, digestive aids) and Vaccines, but in recent years it has shifted its core focus toward higher-value Specialty Medicines such as HIV treatments, respiratory and immunology therapies, and oncology drugs. The fact that Specialty Medicines grew 14% in Q2 and now accounts for nearly half of total revenue means that transformation has been confirmed in the numbers. Profitability is also worth highlighting. While revenue rose 5%, core operating profit grew 7% and core EPS grew 9%. This signals that the mix has shifted toward higher-margin products and that cost discipline is being executed in parallel. On a first-half basis, core EPS reached 97.1 pence, up 9%, showing this was not a one-quarter flash. Shareholder returns continued as well. The Q2 dividend was 17 pence per share, with a full-year expectation of 70 pence. The previously announced £2.0 billion share buyback program was completed this quarter. ## The Negatives

General Medicines -9%: £2.3 billion, contracting and weighing on overall growth

EPS guidance at the low end: Full-year core EPS growth of 7–9% guided to the "lower half"

Pipeline noise: Disappointment from R&D-related setbacks, including the discontinuation of the chronic cough treatment, has been accumulating

The most notable weakness is the General Medicines segment. While Specialty Medicines and Vaccines delivered double-digit and high-single-digit growth respectively, General Medicines declined 9%. This segment is exposed to generic competition because many of its drugs are older and have lost patent protection — and that pressure continues. This is largely why overall growth was capped at 5%. The nuance in guidance also warrants a closer look. Revenue and operating profit were guided to the upper ends of their ranges, but core EPS growth — the metric investors watch most sensitively — was pointed to the lower half. This can be read as a signal that improvements made at the operating level are being partially diluted further down the income statement by taxes, FX, and financial costs. R&D noise adds to the burden. Earlier news of the chronic cough treatment discontinuation has weighed on the stock. For Specialty Medicines growth to continue, new drugs need to emerge smoothly to follow on from the existing flagship products, and market confidence in this area has not yet fully recovered. ## What Management Said

Management's message leans toward confidence that "the growth engines are running as expected." Importantly, rather than merely maintaining full-year revenue and core operating profit guidance, management explicitly pointed to the "upper end" of the ranges. This raises expectations in substance without raising the headline numbers. Within the cautious language pharma typically employs, this sits on the most optimistic end of the spectrum. That said, the tone was not entirely one-sided, as core EPS growth was directed to the lower end of its range. Management explained that GSK is accelerating R&D investment while tightening its cost structure — which can be interpreted as prioritizing the mid-term growth platform over near-term net income. The fact that the release also included commentary on portfolio growth opportunities sits in the same context. ## Market Reaction and Forward Watchpoints

The key question for this earnings report was the "quality of growth." Revenue itself appears to have come in slightly above market expectations (with variation across providers), but what the market really wanted to confirm was whether Specialty Medicines can continue to offset the decline in General Medicines. Specialty Medicines' 14% growth and the Vaccines segment's 8% rebound provide an initial affirmative answer. Because the release came before the US market open, the actual stock reaction will need to be confirmed in the pre-market and regular session. However, reasons for the stock not to move sharply also remain. Recent pipeline-related disappointments had weighed on investor sentiment, and the lower-half EPS guidance is not enough to drive a meaningful re-rating of valuation. GSK is generally classified as a defensive pharma stock with a relatively high dividend yield, so a stable trajectory is a more realistic expectation than a sharp rally. For investors accessing the stock via ADRs, it should also be kept in mind that pound–dollar FX swings flow directly into returns. - Whether the General Medicines revenue decline persists at close to double-digit levels into Q3

Whether Specialty Medicines growth holds in double digits, particularly the contribution from new HIV and oncology products

Whether cost improvements emerge that could lift full-year core EPS growth from the lower half to the midpoint of its range

Whether additional shareholder return plans are announced following the completion of the £2.0 billion buyback